Fig. 5
From: Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy
EVs-Cas9-29b therapy attenuate immobilization induced muscle atrophy in vivo. a Schematic diagram of experimental design process. b qRT-PCR analysis for the expression of miR-29b in gastrocnemius muscle of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 8,8,9,8). c Western blot analysis for Cas9 protein in gastrocnemius muscle of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 6). d Gastrocnemius muscle morphology, weight and Gastrocnemius weight/body Weight ratio of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 8,8,9,8). e qRT-PCR analysis for the expression of Atrogin-1 and MuRF-1 in gastrocnemius muscle of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 8,8,9,8). f–g HE staining and WGA staining for myofiber of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 8,8,9,8; scale bar:100 μm:). h Western blot analysis of AKT/FOXO3A/mTOR pathway (AKT, FOXO3A, mTOR, P70S6K, 4EBP1) in gastrocnemius muscle of mice injected with EVs-Cas9-29b in IMO-induced muscle atrophy (n = 6 per group). Data were presented as mean ± SD. Statistical significance was determined by Two-way ANOVA with Tukey test (b-h). *P < 0.05; **P < 0.01 and ***P < 0.001